Ubs Group Ag Lucid Diagnostics Inc. Transaction History

Ubs Group Ag

$528 Billion
Q1 2025

A detailed history of Ubs Group Ag transactions in Lucid Diagnostics Inc. stock. As of the latest transaction made, Ubs Group Ag holds 5,850 shares of LUCD stock, worth $7,488. This represents 0.0% of its overall portfolio holdings.

Number of Shares

5,850

Holding current value

$7,488

% of portfolio

0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 13, 2025	BUY	$0.79 - $1.59 $4,621 - $9,301	5,850 New	5,850 $8,000
Q3 2024 Nov 14, 2024	BUY	$0.75 - $0.88 $1 - $1	2 New	2 $0
Q4 2023 Feb 09, 2024	BUY	$1.16 - $1.54 $222 - $295	192 Added 3.48%	5,708 $8,000
Q3 2023 Nov 09, 2023	BUY	$1.17 - $1.65 $6,453 - $9,101	5,516 New	5,516 $6,000
Q1 2023 May 12, 2023	SELL	$1.17 - $1.77 $1,178 - $1,782	-1,007 Reduced 28.25%	2,558 $3,000
Q4 2022 Feb 08, 2023	SELL	$1.21 - $2.27 $1,689 - $3,168	-1,396 Reduced 28.14%	3,565 $4,000
Q3 2022 Nov 10, 2022	BUY	$1.53 - $3.45 $572 - $1,290	374 Added 8.15%	4,961 $8,000
Q2 2022 Aug 10, 2022	BUY	$1.73 - $3.44 $5,368 - $10,674	3,103 Added 209.1%	4,587 $10,000
Q1 2022 May 16, 2022	SELL	$2.85 - $5.24 $1,151 - $2,116	-404 Reduced 21.4%	1,484 $5,000
Q4 2021 Feb 14, 2022	BUY	$4.87 - $11.76 $9,194 - $22,202	1,888 New	1,888 $10,000

Others Institutions Holding LUCD

# of Institutions

Shares Held

9.45M

Call Options Held

Put Options Held

Masters Capital Management LLC Atlanta, GA

2.73M
Shares

$3.49 Million
0.21% of portfolio
Alyeska Investment Group, L.P. Chicago, IL

1.89M
Shares

$2.42 Million
0.01% of portfolio
Vanguard Group Inc Valley Forge, PA

889K
Shares

$1.14 Million
0.0% of portfolio
Jim Simons Renaissance Technologies LLC | New York, Ny

459K
Shares

$587,603
0.0% of portfolio
Luminus Management LLC Houston, TX

457K
Shares

$584,504
0.62% of portfolio

View Full List

About Lucid Diagnostics Inc.

Ticker LUCD
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 38,568,500
Market Cap $49.4M
Description
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarc...

More about LUCD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account